Please login to the form below
chronic cough
This page shows the latest chronic cough news and features for those working in and with pharma, biotech and healthcare.
Menlo slumps as itching drug fails mid-stage trial
Menlo Therapeutics has said its phase 2 trial of serlopitant in chronic itching (pruritus) is a bust, blaming the result on a high placebo response rate. ... like rival Vanda Therapeutics did with its rival NK1 drug tradipitant this week – as well as
Latest news
-
Bayer extends alliance with Evotec in women’s health
has been pursued for the treatment of chronic cough.
-
Merck says Afferent’s chronic cough drug clears mid-stage trial
MK-7264 reduces coughs per hour by 37%. Merck &Co's purchase of Afferent Pharma last year was all about a candidate drug for chronic cough - so it will be celebrating ... P2X3 receptors are thought to become over-activated in chronic cough, playing a
-
Merck buys cough drug developer Afferent for $1.25bn
Merck &Co has agreed a deal to buy California biopharma company Afferent Pharma, adding a drug candidate for chronic cough to its pipeline. ... In a statement Merck's R&F head Roger Perlmutter said chronic cough represents "an area of significant unmet
-
BMS takes option to buy fibrosis firm Galecto
It takes the form of a progressive scarring of the lungs, leading to shortness of breath, cough and - in extreme cases - can lead to fatal complications such as heart failure. ... Genoa Pharmaceuticals has an inhaled version of pirfenidone in phase III
-
Pharma firms open up drug libraries to UK researchers
For example, clinical trials are now underway in Manchester to see whether an AZ drug designed originally to treat gastro-oesophageal reflux disease can be used to treat chronic cough.
More from news
Approximately 2 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch June 2016
AF-219, a selective, non-narcotic, oral P2X3 antagonist, is currently in a phase 2b trial for the treatment of refractory, chronic cough and in a phase 2 trial in idiopathic ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- ASH 2022: bad blood but big advances
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- Sanofi/Regeneron’s Dupixent recommended by CHMP for atopic dermatitis in children
- Gilead’s Trodelvy approved by FDA for metastatic breast cancer
- World Health Organization releases new road map for breast cancer
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- Making new year resolutions that can also benefit others
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- Omnichannel communications in Medical Affairs: closing the gap between aspiration and reality
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Meeting healthcare’s rising challenges
- Why female mentorship is so powerful in pharma
- AZ’s COVID-19 vaccine trial to continue after Brazilian volunteer death
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
